Treatment Overview
Leukemia treatment in India is planned according to the exact leukemia subtype, genetic and molecular findings, age, overall health, disease risk and response to initial therapy. Depending on the diagnosis, treatment may involve chemotherapy, targeted therapy, immunotherapy, molecularly guided medicines, supportive care or hematopoietic stem cell transplantation. For selected patients, CAR-T cell therapy or a clinical trial may also be considered.
There is no single GAF leukemia cost sheet. Named partner planning for chemotherapy is $1,500–$8,000+, typically outpatient cycles over 3–6 months. Neighbouring targeted therapy is $8,000–$30,000 (oral or infusion over months). Neighbouring immunotherapy is $15,000–$45,000. Neighbouring molecular targeted therapy is $10,000–$32,000. Neighbouring intrathecal chemotherapy is $3,000–$10,000 (day-care LP or Ommaya access). Neighbouring maintenance therapy is $4,000–$18,000. Neighbouring bone marrow transplantation is $25,000–$70,000 (typically 4–8 weeks in or near the unit). Neighbouring allogeneic stem cell transplant is $30,000–$80,000. Neighbouring CAR-T cell therapy is $80,000–$180,000. Neighbouring bone marrow biopsy is $300–$900 (day-care). Comparable US chemotherapy planning is $10,000–$50,000; the BMT sheet is $150,000–$400,000. These are planning ranges from partner hospital cost sheets, not hospital quotations.
India has specialised haematology and bone marrow transplant centres that manage complex leukemia, including acute leukemia, relapsed disease and patients who may need allogeneic transplantation. AIIMS New Delhi describes dedicated haematology services, advanced leukemia investigations and autologous, allogeneic and haploidentical hematopoietic stem-cell transplantation. That is a published service description, not a GAF ranking.
International patients comparing haematologists commonly start with city lists in Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad. When a graft is already on the table, bone-marrow-transplantation lists in Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad are the live facet. Chemotherapy lists sit under medical oncology in Delhi NCR and Mumbai. Partner haematology hospitals in Delhi NCR, Mumbai and Bengaluru, and in Chennai and Hyderabad, are a typical first filter. City cost sheets include Delhi NCR chemotherapy and Delhi NCR bone marrow transplantation, with the same live cities for Mumbai, Bengaluru, Chennai and Hyderabad. Kolkata, Vellore, Pune, Ahmedabad and Chandigarh may have haematology services, but they are not live GAF catalog cities on this site.
Medical note: Leukemia is not one disease. AML, ALL, CML and CLL have different biology and therefore require different treatment strategies. Fever during neutropenia, uncontrolled bleeding or sudden breathlessness belongs in a local emergency department, not in a WhatsApp message. A treatment plan should be developed by a haematologist or hemato-oncologist after reviewing blood, bone marrow, cytogenetic and molecular results.
Leukemia Treatment at a Glance
| Factor | What patients should know |
|---|---|
| Disease family | Blood-forming tissues, not a single solid tumour |
| Main subtypes | AML, ALL, CML, CLL |
| Named chemotherapy sheet | $1,500–$8,000+; outpatient cycles, 3–6 months typical |
| Neighbouring targeted therapy | $8,000–$30,000 |
| Neighbouring immunotherapy | $15,000–$45,000 |
| Neighbouring BMT | $25,000–$70,000; typically 4–8 weeks in or near the unit |
| Neighbouring allogeneic HSCT | $30,000–$80,000 |
| Neighbouring CAR-T | $80,000–$180,000; different cellular-therapy product |
| Specialist | Haematologist / hemato-oncologist |
| Emergency | Neutropenic fever, uncontrolled bleeding or breathlessness belongs in a local emergency department |
What Is Leukemia?
Leukemia is a cancer of blood-forming tissues. It develops when abnormal blood-forming cells acquire changes that allow them to multiply and survive abnormally. These cells can accumulate in the bone marrow and interfere with normal production of red blood cells, healthy white blood cells and platelets.
Because leukemia affects the blood and bone marrow rather than forming a single solid tumour in the way many cancers do, its diagnosis and treatment are different from cancers such as breast, lung or colon cancer.
There are several forms of leukemia, and they behave differently. Some progress rapidly and require urgent treatment, while others develop slowly and may initially be monitored without immediate therapy.
Ask whether treatment is urgent
Types of Leukemia
The four major types are AML, ALL, CML and CLL. AML, ALL, CML and CLL treatment pages are not live on this site. Use this pillar page plus the named modality sheets.
1. Acute myeloid leukemia (AML)
AML is an aggressive leukemia involving abnormal myeloid blood-forming cells. It generally requires prompt evaluation and treatment.
Modern AML treatment incorporates cytogenetic and molecular information. Mutations and chromosomal abnormalities can influence risk classification and may identify targets for specific medicines. Measurable residual disease can also help assess treatment response.
Common approaches include intensive chemotherapy for appropriate patients, lower-intensity combinations, targeted therapy for particular molecular abnormalities, consolidation, maintenance in selected circumstances, allogeneic stem cell transplantation for selected patients, supportive transfusions and infection management, and treatment of relapsed or refractory disease.
Acute promyelocytic leukemia (APL), a distinct subtype of AML, requires a specialised approach and urgent management by an experienced leukemia team.
2. Acute lymphoblastic leukemia (ALL)
ALL develops from lymphoid precursor cells and can affect both children and adults.
Treatment generally involves remission induction, CNS-directed therapy, consolidation or intensification and, in many protocols, prolonged maintenance. Treatment can differ substantially between children, adolescents, young adults and older adults.
Some patients have Philadelphia chromosome-positive (Ph-positive) ALL, in which BCR::ABL1-targeted tyrosine kinase inhibitors form an important part of treatment. Immunotherapies such as blinatumomab and inotuzumab ozogamicin may be used in appropriate situations. Neighbouring intrathecal chemotherapy is $3,000–$10,000 when CNS-directed drug is named separately.
3. Chronic myeloid leukemia (CML)
CML is a myeloid leukemia characterised in most patients by the BCR::ABL1 fusion associated with the Philadelphia chromosome.
Unlike acute leukemias, CML is commonly managed with oral tyrosine kinase inhibitors that target abnormal BCR::ABL1 signalling. Modern monitoring relies on molecular testing to determine how deeply the leukemia is responding.
Depending on treatment response, disease phase and individual circumstances, doctors may consider different TKIs, treatment modification and, in selected advanced or resistant cases, allogeneic stem cell transplantation. Neighbouring targeted therapy is $8,000–$30,000.
4. Chronic lymphocytic leukemia (CLL)
CLL is a usually slow-growing leukemia involving abnormal lymphocytes. It is predominantly an adult disease and may be discovered incidentally on a routine blood test.
Not every patient with CLL needs immediate treatment. Observation can be appropriate when there are no significant symptoms or evidence of progressive disease. When treatment becomes necessary, options can include targeted therapies, chemotherapy in selected circumstances, immunotherapy and, for specific patients, stem cell transplantation or other advanced approaches.
Leukemia Symptoms
Possible symptoms include persistent fatigue or weakness, fever, recurrent infections, easy bruising, unexplained bleeding, nosebleeds or bleeding gums, pale skin, shortness of breath, unexplained weight loss, night sweats, bone or joint pain, enlarged lymph nodes, abdominal fullness from an enlarged spleen or liver, and frequent or prolonged infections.
These symptoms are not specific to leukemia. A persistent abnormal blood count, unexplained bruising or bleeding, recurrent infections or other concerning symptoms should be assessed by a doctor rather than assumed to be leukemia.
How Is Leukemia Diagnosed?
Leukemia diagnosis usually requires more than a routine blood test.
Complete blood count. A CBC measures haemoglobin, white cells and platelets. Abnormalities may raise suspicion, but a CBC alone generally cannot determine the exact subtype.
Peripheral blood smear. A pathologist examines blood cells under a microscope.
Bone marrow aspiration and biopsy. A sample is usually obtained from the pelvic bone. Neighbouring bone marrow biopsy is $300–$900 (day-care). Aspiration may be paired on the same sitting.
Depending on the suspected leukemia, doctors may add morphological examination, flow cytometry, cytogenetic testing, FISH, molecular testing, mutation analysis and measurable residual disease assessment. Neighbouring precision oncology is $2,000–$7,000 when an NGS panel plus clinic visit is the named product.
Share reports for a leukemia opinion
Why Molecular Testing Matters in Leukemia
Two patients who appear to have the same broad leukemia subtype may have different genetic or molecular abnormalities and therefore require different treatment strategies.
Molecular findings can identify potentially actionable mutations in AML. BCR::ABL1 testing is central to the diagnosis and monitoring of CML. In ALL, genetic findings such as Philadelphia chromosome positivity can significantly influence therapy.
When seeking leukemia treatment in India, ask whether the hospital has access to flow cytometry, cytogenetics, FISH, PCR-based molecular testing, next-generation sequencing where clinically appropriate, BCR::ABL1 testing, MRD testing and HLA typing if transplantation may be discussed.
What Is Measurable Residual Disease (MRD)?
Measurable residual disease refers to leukemia cells that remain after treatment at levels below what may be detectable through conventional examination.
MRD assessment is particularly important in several acute leukemias because the presence or absence of detectable residual disease can provide additional information about treatment response and future risk.
In practical terms, MRD helps doctors answer: how deeply has the leukemia responded to treatment? The exact test and its interpretation depend on the subtype.
Leukemia Treatment Options in India
Leukemia treatment is individualised. Depending on the diagnosis, treatment may include one or more of the following.
1. Chemotherapy
Chemotherapy uses medicines that destroy rapidly dividing leukemia cells. It remains important for many acute leukemias.
For AML, intensive chemotherapy may be used in patients who are suitable for it, while lower-intensity approaches may be appropriate for patients who are not candidates for intensive treatment. For ALL, combination chemotherapy remains a major component, generally delivered through different phases.
Named chemotherapy is $1,500–$8,000+. Drugs, doses and schedule depend entirely on the subtype and protocol.
2. Targeted therapy
Targeted therapy attacks specific molecular pathways. Examples include tyrosine kinase inhibitors for BCR::ABL1-positive leukemia, FLT3-targeted therapy in selected AML, IDH-targeted therapies in selected AML, BCL-2-directed therapy in appropriate AML settings and other molecularly directed treatments.
Named targeted therapy is $8,000–$30,000. Neighbouring molecular targeted therapy is $10,000–$32,000 when a documented mutation is the product.
3. Immunotherapy
Depending on the disease, approaches may include monoclonal antibodies, bispecific antibodies, antibody-drug conjugates and other immune-based treatments. For ALL, drugs such as blinatumomab and inotuzumab may be considered in appropriate circumstances.
Named immunotherapy is $15,000–$45,000. Neighbouring antibody-drug conjugate therapy is $25,000–$70,000.
4. CAR-T cell therapy
CAR-T therapy collects a patient's T cells, genetically modifies them to recognise cancer cells and returns them to the patient. It is not appropriate for every leukemia patient.
Eligibility depends on subtype, disease status, previous treatments, age and health, availability of an approved product, centre expertise and regulatory or trial considerations.
Neighbouring CAR-T cell therapy is $80,000–$180,000 (apheresis plus 3–6 weeks nearby). It is a different cellular-therapy product from BMT.
5. Stem cell transplant / bone marrow transplant
In leukemia, an allogeneic transplant — using stem cells from another person — is particularly important in selected high-risk situations.
A transplant may be considered based on subtype, genetic risk, response to initial treatment, MRD status, relapse or refractory disease, age, general health, donor availability and expected transplant-related risks.
Potential sources include a matched sibling, a matched unrelated donor, a haploidentical family donor and, in selected settings, umbilical cord blood.
Named transplant lists sit on Bone Marrow Transplant in India. The BMT sheet is $25,000–$70,000. Neighbouring allogeneic is $30,000–$80,000. Neighbouring haploidentical is $35,000–$85,000. Neighbouring matched unrelated-donor is $40,000–$95,000. Neighbouring paediatric BMT is $28,000–$75,000.
6. Supportive care
Supportive treatment may include red-cell and platelet transfusions, antibiotics, antiviral or antifungal treatment, growth-factor support, nausea management, nutrition, tumour-lysis precautions, infection prevention, bleeding management and fertility-preservation discussions where relevant.
Request a named-protocol cost estimate
Leukemia Treatment by Type
| Leukemia type | Common treatment approaches |
|---|---|
| AML | Intensive or lower-intensity chemotherapy, targeted therapy, consolidation, selected maintenance, stem cell transplant, supportive care |
| APL | Specialised differentiation-based treatment with or without chemotherapy |
| ALL | Combination chemotherapy, CNS-directed treatment, targeted therapy for selected subtypes, immunotherapy, maintenance, transplant in selected patients |
| CML | Tyrosine kinase inhibitors, molecular monitoring, transplant in selected advanced or high-risk cases |
| CLL | Observation when appropriate, targeted therapy, selected immunotherapy or chemotherapy, cellular or transplant approaches in selected difficult cases |
Treatment should not be selected solely from this table. The precise protocol is determined by a haematologist after reviewing diagnostic and molecular results.
Leukemia Treatment for Children
Childhood leukemia requires specialised paediatric haematology-oncology care. The approach is different from many adult protocols, particularly for ALL.
Childhood ALL may include remission induction, CNS-directed therapy, consolidation or intensification, maintenance, targeted or immunotherapy in selected cases, and stem cell transplantation in selected high-risk or relapsed disease.
Childhood AML similarly involves intensive disease-directed therapy, CNS-directed treatment where appropriate, supportive care and, for selected patients, donor stem cell transplantation.
Families travelling to India should look for a dedicated paediatric hemato-oncology and paediatric BMT programme. Neighbouring pediatric bone marrow transplantation is $28,000–$75,000. Adult transplant floors are not a substitute because a brochure says they treat all ages.
Paediatric doctor lists include Delhi NCR paediatric haematology and Chennai paediatric haematology.
Share a child's reports for a paediatric leukemia opinion
Leukemia Treatment for Adults
Adult leukemia treatment depends on age, functional status, other medical conditions, subtype, genetic risk, disease burden, treatment response, MRD, previous treatment and transplant eligibility.
For AML, treatment intensity is not determined by age alone. Fitness, comorbidities and disease biology decide intensive versus less-intensive treatment. Older adults can benefit from a personalised plan rather than an automatic assumption that intensive treatment is unsuitable.
Treatment of Relapsed or Refractory Leukemia
Some leukemias return after remission. Others fail to achieve the expected response to initial treatment.
Options may include salvage chemotherapy, targeted therapy, immunotherapy, bispecific antibodies, cellular therapy, clinical trials and allogeneic stem cell transplantation. The choice depends on the subtype, molecular profile and prior treatment.
Request a relapsed-leukemia review
Leukemia Treatment Cost in India
There is no single leukemia treatment cost in India because leukemia is a group of diseases. Treatment may range from long-term oral targeted therapy to intensive chemotherapy, hospitalisation and stem cell transplantation.
A CML patient who responds to an oral TKI has a different pathway from an AML patient who needs intensive chemotherapy, prolonged hospitalisation, multiple transfusions and an allogeneic transplant. A child with ALL may require a prolonged multi-phase programme.
International patients should ask hospitals to provide a written estimate separating initial evaluation, diagnostic work-up, treatment drugs, hospitalisation, supportive care, ICU, stem cell transplant, follow-up and what is excluded if complications occur.
WhatsApp +91 90443 46292 for an itemised leukemia estimate
How to Choose a Leukemia Centre in India
There is no single hospital that is best for every leukemia patient.
Look for a dedicated haematology or hemato-oncology team that already treats the relevant subtype, access to flow cytometry, cytogenetics, molecular testing and MRD, a blood bank, infection-control and ICU support, and — if a graft may be needed — a transplant unit that already performs allogeneic or haploidentical work.
Live GAF city lists currently cover Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad. Kolkata, Vellore, Pune, Ahmedabad and Chandigarh are not live GAF catalog cities on this site.
Catalog haematologists currently tagged to leukemia or blood-cancer lists include Dr. Ajay Gupta and Dr. Akash Khandelwal in Delhi NCR; Dr. Akshay Shah and Dr. Muralidaran C in Mumbai; Dr. Govind Eriat and Dr. Neema Bhat in Bengaluru; Dr. M. Gopinathan and Dr. Prabu P in Chennai; and Dr. K. Karuna Kumar and Dr. Narender Kumar Thota in Hyderabad. Neighbouring paediatric leukemia lists include Dr. Amita Mahajan in Delhi NCR, Dr. Vipin Khandelwal in Mumbai, Dr. Prerana Nesargi in Bengaluru, Dr. G. Vimal Kumar in Chennai and Dr. Parinitha Reddy Gutha in Hyderabad. A catalog tag is not a volume, outcome or ranking claim.
Catalog hospitals currently affiliated with those tagged lists include Indraprastha Apollo Hospital, BLK-Max Super Speciality Hospital and Medanta - The Medicity in Delhi NCR; Wockhardt Hospital, Mumbai and Gleneagles Hospital, Mumbai; Apollo Hospitals, Bannerghatta Road and Gleneagles Hospitals, Bengaluru; Apollo Hospital, Chennai and MGM Healthcare, Chennai; and Yashoda Hospitals, Secunderabad and KIMS Hospitals, Secunderabad.
Find a leukemia specialist in India
WhatsApp +91 90443 46292 to match a haematologist
- Haematology hospitals in Delhi NCR
- Haematology hospitals in Mumbai
- Haematology hospitals in Bengaluru
- Haematology hospitals in Chennai
- Haematology hospitals in Hyderabad
Leukemia Treatment Process in India for International Patients
Step 1: Send medical records
The initial file may include CBC reports, peripheral smear, bone marrow reports, flow cytometry, cytogenetic or FISH reports, molecular results, imaging, previous chemotherapy records, discharge summaries, transfusion history and current medicines.
Step 2: Haematologist review
A specialist reviews the available records and determines the likely diagnosis, additional tests required, treatment urgency, potential options and whether transplant assessment may be needed.
Step 3: Treatment plan and estimate
The hospital can then provide an individualised plan and estimated cost from named modality sheets. Ask which investigations need to be repeated after arrival.
Step 4: Travel and admission
Once medically appropriate, the international-patient team can coordinate admission. For suspected or newly diagnosed acute leukemia, ask about travel urgency before booking flights.
Step 5: Treatment
Treatment may involve outpatient care, day-care treatment, prolonged hospitalisation or a combination of these.
Step 6: Response assessment
The team evaluates response through blood counts, bone marrow testing, molecular testing and MRD as appropriate.
Step 7: Long-term follow-up
Follow-up may involve CBC monitoring, molecular testing, MRD, medication monitoring, infection surveillance, organ-function testing, late-effect monitoring and transplant follow-up.
Plan a leukemia treatment journey
What Medical Records Should You Send?
Essential reports include complete blood count, peripheral blood smear, bone marrow aspiration and biopsy, flow cytometry, cytogenetics or karyotype, FISH, molecular or genetic testing, BCR::ABL1 if relevant and MRD if available.
Previous treatment records should name the protocol, drugs and doses, cycles completed, response assessment, previous transplant details, complications and transfusion history.
Current clinical information should include age, weight, symptoms, infections, medicines, other medical conditions, kidney and liver function and performance status.
Questions to Ask a Leukemia Specialist in India
- What exact type of leukemia do I have?
- Is it acute or chronic?
- What genetic or molecular abnormalities have been identified?
- What is my risk category?
- Do I need treatment immediately?
- What is the goal of treatment?
- What treatment protocol do you recommend?
- Will I need hospitalisation?
- How many treatment cycles are expected?
- Will I need a stem cell transplant?
- How will you determine whether treatment is working?
- Will MRD testing be used?
- What are the major treatment-related risks?
- How will infections and low blood counts be managed?
- What happens if the leukemia does not respond?
- What happens if the leukemia returns?
- Are targeted therapies appropriate for my leukemia?
- Are clinical trials available?
- What is the estimated treatment cost from named sheets?
- Which parts of the estimate are not included?
Leukemia Treatment and Fertility
Some leukemia treatments can affect fertility. This is particularly important for children, adolescents and younger adults. Where clinically safe and practical, discuss fertility preservation before starting treatment, because urgent leukemia treatment may limit the time available.
Nutrition During Leukemia Treatment
There is no special diet proven to eliminate leukemia. Priorities generally include adequate calories and protein, safe food handling, hydration and management of nausea or weight loss. Patients with severe neutropenia or during transplantation may receive specific food-safety recommendations. Be cautious about herbal products or supplements that can interact with cancer medicines.
Leukemia and Infection Risk
Leukemia itself and intensive chemotherapy can reduce normal immune defences. During periods of severe neutropenia, fever can require urgent medical assessment.
A leukemia patient receiving intensive treatment who develops fever should contact the treating medical team immediately. If fever, uncontrolled bleeding or breathlessness develops away from the unit, go to a local emergency department. Do not wait for a WhatsApp reply.
Can Leukemia Be Cured?
The answer depends on the type of leukemia, its molecular characteristics, disease risk, response to treatment and whether it has relapsed.
Some leukemias can enter long-term remission. Others can be controlled for many years with ongoing medication. Modern CML therapy with TKIs has changed the long-term outlook for many patients. Acute leukemias require a different approach, where achieving and maintaining remission through consolidation, maintenance, transplantation or other therapies may be central.
It is more useful to discuss the specific subtype and individual risk profile than to ask whether leukemia as a whole is curable.
Frequently Asked Questions About Leukemia Treatment in India
What is the best treatment for leukemia?
There is no single treatment that is best for every leukemia patient. Treatment depends on whether the patient has AML, ALL, CML, CLL or another subtype, as well as genetic findings, age, health, disease risk and treatment response.
Is leukemia treatment available in India?
Yes. Major Indian tertiary hospitals provide haematology, hemato-oncology and stem cell transplantation services for leukemia.
Is leukemia treatment in India affordable?
There is no single package. Named chemotherapy is $1,500–$8,000+. Targeted therapy is $8,000–$30,000. BMT is $25,000–$70,000. A patient-specific quotation is more meaningful than a generic leukemia cost figure.
Does every leukemia patient need a bone marrow transplant?
No. Many patients are managed without transplantation. Transplant is considered for selected patients based on disease biology, relapse risk, treatment response, MRD, age, health and donor availability. Transplant lists sit on Bone Marrow Transplant in India.
Is chemotherapy necessary for CML?
Not necessarily. CML is commonly treated with oral tyrosine kinase inhibitors directed at BCR::ABL1. Treatment decisions depend on disease phase and response.
Can CLL be treated without chemotherapy?
Yes. Some patients with CLL can initially be monitored without treatment, and targeted therapies are important options when therapy becomes necessary.
How long does leukemia treatment take?
There is no universal timeline. ALL treatment may extend over years because of maintenance therapy. AML often involves intensive treatment over several phases. CML may require long-term oral therapy. CLL may be observed for a period before treatment is needed.
Can leukemia come back after treatment?
Yes. The options for relapse depend on the subtype, previous therapy, molecular findings and current disease status.
What is the difference between leukemia and lymphoma?
Leukemia primarily involves abnormal blood and bone marrow cells, while lymphoma typically forms masses in lymph nodes or other lymphatic tissues. There can be overlap. Lymphoma lists sit on Lymphoma Treatment in India.
What is acute leukemia?
Acute leukemia generally progresses rapidly and involves immature blood-forming cells. AML and ALL are the two major acute categories. Suspected cases require prompt specialist evaluation.
What is chronic leukemia?
Chronic leukemia generally progresses more slowly. CML and CLL are the two major chronic categories. Some patients may not require immediate treatment at diagnosis.
Can leukemia be treated successfully in children?
Many childhood leukemias are highly treatable, but the outcome depends on the exact subtype, risk group, genetics, treatment response and other factors. Children should ideally be treated at specialised paediatric hemato-oncology centres.
Is a second opinion useful for leukemia?
A second opinion can be particularly useful when the diagnosis is complex, transplantation is being considered, molecular testing reveals an unusual abnormality, or the disease has relapsed. The second specialist should review the original pathology, flow cytometry, molecular and bone marrow results.
Does CAR-T use the leukemia chemotherapy sheet?
No. Neighbouring CAR-T cell therapy is $80,000–$180,000 and is a different cellular-therapy product.
Which city in India is best for leukemia treatment?
There is no single best city. Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad are live GAF catalog cities. Choose a named haematology unit that already treats the relevant subtype.
Key Takeaways
- Leukemia treatment in India is highly individualised. The first step is to establish the exact subtype and its molecular characteristics.
- Treatment may involve chemotherapy, targeted therapy, immunotherapy, long-term oral medicines, supportive care, stem cell transplantation or newer cellular therapies.
- There is no single GAF leukemia package. Named chemotherapy is $1,500–$8,000+. Neighbouring targeted therapy is $8,000–$30,000. Neighbouring BMT is $25,000–$70,000.
- Transplant lists sit on Bone Marrow Transplant in India.
- Fever during neutropenia, uncontrolled bleeding or breathlessness belongs in a local emergency department.
Share CBC, smear, marrow, flow cytometry, cytogenetics or FISH, molecular testing and previous treatment records before making travel arrangements.
Request a leukemia treatment plan
Share records for a leukemia review
Message a coordinator on WhatsApp
Request a cost review on WhatsApp
Why GAF Healthcare Can Help International Patients
For an international patient, arranging leukemia treatment involves medical-record collection, specialist review, hospital coordination, treatment estimates, appointment scheduling, travel planning, local assistance and follow-up coordination.
GAF Healthcare can help coordinate the process with appropriate hospitals and haematology teams. A medical opinion should always come from the treating haematologist or hemato-oncologist. GAF Healthcare's role is to facilitate access and coordination rather than replace the medical team.
Related Treatment and Cost Guides
- Bone Marrow Transplant in India — named BMT sheet $25,000–$70,000
- Chemotherapy — $1,500–$8,000+
- Targeted therapy — $8,000–$30,000
- Immunotherapy — $15,000–$45,000
- Molecular targeted therapy — $10,000–$32,000
- CAR-T cell therapy — $80,000–$180,000
- Allogeneic stem cell transplant — $30,000–$80,000
- Pediatric bone marrow transplantation — $28,000–$75,000
- Bone marrow biopsy — $300–$900
AML, ALL, CML, CLL and blood-cancer treatment pages are not live on this site. Lymphoma lists sit on Lymphoma Treatment in India. Thalassemia lists sit on Thalassemia Treatment in India. Sickle cell lists sit on Sickle Cell Anemia Treatment in India. Myeloma lists sit on Multiple Myeloma Treatment in India. Aplastic anemia lists sit on Aplastic Anemia Treatment in India. Autologous transplant lists sit on Autologous Bone Marrow Transplant in India. Fanconi anemia lists sit on Fanconi Anemia Treatment in India.
Chemotherapy, targeted-therapy and transplant lists treat different briefs. They are not a substitute leukemia package.
Top 10 Medical Sources
- National Cancer Institute — Leukemia — overview of leukemia types and treatment families.
- National Cancer Institute — AML treatment — AML approaches and response assessment.
- National Cancer Institute — ALL treatment — adult ALL phases and CNS-directed therapy.
- National Cancer Institute — CML treatment — TKI therapy and molecular monitoring.
- National Cancer Institute — CLL treatment — observation and treatment options.
- European LeukemiaNet — CML recommendations — contemporary CML management.
- ASH / ELN AML recommendations — AML diagnosis, molecular risk, MRD and treatment.
- GAF Healthcare bone marrow transplantation — partner USD planning of $25,000–$70,000.
- GAF Healthcare chemotherapy — partner USD planning of $1,500–$8,000+.
- Mayo Clinic — Leukemia — diagnostic investigations and general treatment overview.
Last reviewed against the cited sources: October 2026.
Medical Disclaimer
This page is intended for general educational purposes and should not replace an examination, diagnosis or individualized medical advice from a qualified haematologist or hemato-oncologist.
Leukemia treatment is individualized. Suitability, protocol, risks, recovery and expected results vary from patient to patient. Treatment protocols and drug availability can change as evidence and regulatory approvals evolve.
If you develop fever during neutropenia, uncontrolled bleeding, sudden confusion or breathlessness, seek urgent medical attention in a local emergency department.
Treatment Process
- 1
Share reports
The patient provides CBC, smear, marrow, flow, cytogenetic, molecular and previous-treatment notes.
- 2
Virtual haematology opinion
A haematologist reviews whether the case is AML, ALL, CML, CLL or another clone and whether travel is urgent.
- 3
Name the protocol family
The team writes chemotherapy, targeted therapy, immunotherapy, CAR-T or transplant as separate products.
- 4
Itemized estimate
There is no single leukemia package. Named chemotherapy is $1,500–$8,000+. BMT is $25,000–$70,000.
- 5
Travel to India
Stable planned cases travel after records review. Neutropenic fever or uncontrolled bleeding is a local emergency.
- 6
Repeat essential tests
The receiving unit confirms subtype, organ function and infection status after arrival.
- 7
Deliver the named protocol
Induction, TKI therapy, immunotherapy or conditioning proceeds only after the clone is named.
- 8
Response and MRD
Counts, marrow and residual-disease tests decide the next line, including whether a graft is honest.
- 9
Return home
The patient leaves with drug lists, infection rules, warning signs and a remote-follow-up plan.
